
Sign up to save your podcasts
Or


In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ainhoa Madariaga to discuss parp inhibitor treatments and adverse events. Dr. Madariaga's article, "Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events," (https://ijgc.bmj.com/content/early/2020/06/08/ijgc-2020-001288) is the Lead Article in the July 2020 issue of IJGC. Dr. Madariaga is a medical oncologist working as a clinical research fellow in the gynecology and drug development program at Princess Margaret Cancer Centre. Her clinical and academic areas of interest are gynecologic cancers and early phase clinical trial design; such as development of drug-repurposing studies, cancer treatment adverse event and patient reported outcomes assessment.
By BMJ Group5
2323 ratings
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ainhoa Madariaga to discuss parp inhibitor treatments and adverse events. Dr. Madariaga's article, "Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events," (https://ijgc.bmj.com/content/early/2020/06/08/ijgc-2020-001288) is the Lead Article in the July 2020 issue of IJGC. Dr. Madariaga is a medical oncologist working as a clinical research fellow in the gynecology and drug development program at Princess Margaret Cancer Centre. Her clinical and academic areas of interest are gynecologic cancers and early phase clinical trial design; such as development of drug-repurposing studies, cancer treatment adverse event and patient reported outcomes assessment.

37 Listeners

52 Listeners

5 Listeners

8 Listeners

5 Listeners

3 Listeners

2 Listeners

3 Listeners

8 Listeners

38 Listeners

14 Listeners

1 Listeners

51 Listeners

0 Listeners

6 Listeners

14 Listeners

3 Listeners

3 Listeners

23 Listeners